SCHEMBL4735946

SCHEMBL4735946

CCOC(=O)c1cc2c(nc(C)n2C)c(O)c1CCC(=O)c1ccccc1C

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ELANE P08246 1/20 0.40
TSHR P16473 2/20 0.39
ALDH1A1 P00352 5/20 0.38
MAPT P10636 4/20 0.38
GAA P10253 3/20 0.38
HPGD P15428 3/20 0.38
POLB P06746 2/20 0.37
PKM P14618 1/20 0.37
RAB9A P51151 1/20 0.37
KDM4E B2RXH2 3/20 0.36
KMT2A Q03164 2/20 0.36
GLA P06280 1/20 0.36
STAT6 P42226 1/20 0.36
HIF1A Q16665 1/20 0.36
MAPK1 P28482 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
CCR6 P51684 1/20 0.35
TP53 P04637 1/20 0.35
HSD17B10 Q99714 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4664575 0.89 KMT2A (0.41) ELANETSHRALDH1A1MAPTGAA
SCHEMBL4964892 0.85 TSHR (0.38) TSHRALDH1A1GAAHPGDRAB9A
SCHEMBL4962551 0.85 CTNNB1 (0.35) ALDH1A1HPGDRAB9AKMT2AMAPK1
SCHEMBL4963781 0.85 CTNNB1 (0.35) ALDH1A1GAAHPGDRAB9AKDM4E
SCHEMBL4961356 0.83 HTT (0.43) TSHRALDH1A1POLBKMT2A
SCHEMBL4738299 0.83 HTT (0.46) TSHRALDH1A1POLBKMT2A
SCHEMBL4964158 0.82 NPC1 (0.36) MAPTPOLBPKMRAB9AKMT2A
SCHEMBL4963521 0.81 NPC1 (0.42) ALDH1A1POLBRAB9AKMT2AGLA
SCHEMBL4664863 0.80 LMNA (0.40) TSHRALDH1A1MAPTGAAHPGD
SCHEMBL4965054 0.78 HCRTR1 (0.32) POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080280855-A1 Process For the Production of Intermediates For the Preparation of Tricyclic Benzimidazoles NYCOMED GMBH (DE) 2008-11-13 US disclosed
WO-2008074858-A1 INTERMEDIATES AND PROCESS FOR THE PRODUCTION OF 5-SUBSTITUTED TRICYCLIC BENZIMIDAZOLES NYCOMED GMBH (DE) 2008-06-26 WO disclosed
EP-1904454-A2 PROCESS FOR THE PRODUCTION OF INTERMADIATES FOR THE PREPARATION OF TRICYCLIC BENZIMIDAZOLES Nycomed GmbH (DE) 2008-04-02 EP disclosed
WO-2006136552-A2 PROCESS FOR THE PRODUCTION OF INTERMADIATES FOR THE PREPARATION OF TRICYCLIC BENZIMIDAZOLES NYCOMED GMBH (DE) 2006-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280855-A1 Process For the Production of Intermediates For the Preparation of Tricyclic Benzimidazoles CYP1B1, CYP1A1, CYP3A4 ELANE 4534/4885TSHR 1192/4885ALDH1A1 76/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.